265 related articles for article (PubMed ID: 29345156)
1. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Svetel M; Tomić A; Kresojević N; Kostić V
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
[TBL] [Abstract][Full Text] [Related]
2. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
3. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
[TBL] [Abstract][Full Text] [Related]
4. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
5. Opicapone: A Review in Parkinson's Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
[TBL] [Abstract][Full Text] [Related]
6. The preclinical discovery and development of opicapone for the treatment of Parkinson's disease.
Ettcheto M; Busquets O; Sánchez-Lopez E; Cano A; Manzine PR; Verdaguer E; Olloquequi J; Auladell C; Folch J; Camins A
Expert Opin Drug Discov; 2020 Sep; 15(9):993-1004. PubMed ID: 32450711
[TBL] [Abstract][Full Text] [Related]
7. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
[TBL] [Abstract][Full Text] [Related]
8. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
[TBL] [Abstract][Full Text] [Related]
9. Opicapone: A Review in Parkinson's Disease.
Scott LJ
CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
[TBL] [Abstract][Full Text] [Related]
10. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
11. The launch of opicapone for Parkinson's disease: negatives versus positives.
Castro Caldas A; Teodoro T; Ferreira JJ
Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
[TBL] [Abstract][Full Text] [Related]
12. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
13. Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
Lee JY; Ma HI; Ferreira JJ; Rocha JF; Sung YH; Song IU; Ahn TB; Kwon DY; Cheon SM; Kim JM; Lee CS; Lee PH; Park JH; Lee JH; Park MY; Kim SJ; Baik JS; Choi SM; Shin HW; Lee HW; Kang SY; Jeon B
Mov Disord Clin Pract; 2024 Jun; 11(6):655-665. PubMed ID: 38594812
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.
Gonçalves D; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Toxicol Appl Pharmacol; 2017 May; 323():9-15. PubMed ID: 28322896
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
Kitajima T; Mizote S; Bonifácio MJ; Umemura T; Yoneda K; Moser P; Soares-da-Silva P; Tanaka M
Neuropharmacology; 2018 Dec; 143():282-288. PubMed ID: 30290160
[TBL] [Abstract][Full Text] [Related]
16. Objective assessment of the effects of opicapone in Parkinson's disease through kinematic analysis.
Bologna M; Guerra A; Colella D; Birreci D; Costa D; Cannavacciuolo A; Angelini L; Paparella G; Antonini A; Berardelli A; Fabbrini G
Neurol Sci; 2024 May; 45(5):2035-2046. PubMed ID: 38091213
[TBL] [Abstract][Full Text] [Related]
17. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Ferreira JJ
Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
[TBL] [Abstract][Full Text] [Related]
19. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
[TBL] [Abstract][Full Text] [Related]
20. Opicapone for the treatment of Parkinson's disease.
Rodrigues FB; Ferreira JJ
Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
